Navigation Links
Amsterdam Molecular Therapeutics Announces € 2.5 Million Equity Raise
Date:12/30/2011

ivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world's first stable and scalable AAV manufacturing platform. This proprietary platform can be applied to a large number of rare (orphan) diseases caused by one faulty gene and allows AMT to pursue its strategy of focusing on this sector of the industry.  AMT was founded in 1998 and is based in Amsterdam. Further information can be found at http://www.amtbiopharma.com.

 

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of AMT only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business. AMT expressly disclaims any intent or obligation to update any forward-looking statements herein except as required by law. 



'/>"/>
SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amsterdam Molecular Therapeutics Announces Negative Equity Position
2. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
3. Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline
4. Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
5. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
7. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
10. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
11. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , 22 de enero de 2015  El Dr. ... su llamada a nominaciones para 2015. Este prestigioso premio ... o tiene el potencial para hacer, contribuciones destacadas para ... aceptarán hasta el 15 de marzo de 2015 a ...
(Date:1/22/2015)... , Jan. 22, 2015  Derma Sciences, Inc. ... company focused on advanced wound care, announces that ... tissues, have been added to the Premier, Inc. ... the opportunity for the AMNIOEXCEL® and AMNIOMATRIX® product ...
(Date:12/24/2014)... AUSTIN, Texas , Dec. 24, 2014  Vermillion, ... focused on gynecologic disease, announced today that the ... investors including Oracle Investment Management, Jack W. ... directors. Total proceeds were $10.5 million, before offering ...
(Date:12/24/2014)... Earlier this year in a June 24 ... Adult Stem Cell Technology Center, LLC ( ASCTC ) focused ... of adult tissue stem cells. His title “Asymmetric Self-Renewal ... the Future,” embodied the essence of his message to congress ...
Breaking Biology Technology:El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... Devgen,(Eurolist: DEVG) and Monsanto Company (NYSE: MON ... which Monsanto has agreed, subject to certain,customary conditions, to ... 18 million (25 million $) and representing 5.9%,of the ... take place,no later than November 2007. It is ...
... announces today,that a service agreement with Roche Diagnostics ... its automated immunohistochemistry,service platform for analyzing various biomarkers ... will provide for this project a selection of,tumor ... as specifically,collected clinical samples. The analysis of specific ...
... Nationally, SCOTTSDALE, Ariz., Sept. 14 CHS, an ... by the U.S. Department,of Defense as a recipient of ... award, sponsored by the National Committee of Employer,Support of ... honor,bestowed upon America,s employers who provide support to their ...
Cached Biology Technology:Monsanto Company Signs Share Subscription Agreement With Devgen 2Monsanto Company Signs Share Subscription Agreement With Devgen 3CHS Receives Prestigious Honor from Department of Defense 2CHS Receives Prestigious Honor from Department of Defense 3
(Date:12/24/2014)... , Dec. 23, 2014  Since its launch in December 2014, the ... eliminate the pain of trying to remember their usernames and ... fused to their smartphones. To assist people who have struggled ... company that created 1U and focuses on redefining identity, announced ...
(Date:12/19/2014)... Dec. 18, 2014 Research and Markets ( ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire ... http://photos.prnewswire.com/prnh/20130307/600769 Following ... the fingerprint reading feature with the iPhone 5S. It ...
(Date:12/17/2014)... , Dec. 15, 2014 Research and Markets ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint ... http://photos.prnewswire.com/prnh/20130307/600769 Based ... 5S, Samsung introduces for the first time a fingerprint ...
Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... <a target="_blank" href="http://en.wikipedia.org/wiki/Nucleic_acid_sequence,">DNA sequences come in various ... and discard compromised molecular data has thus become ... one that everyone generating sequence data is assumed ... research purposes. "Many researchers find sequence quality ...
... increasing salt concentrations are stress factors that many ecosystems ... do all ecosystems react to stress in the same ... services, such as biomass production? Botanists and ecologists from ... high level of biodiversity aids stress resistance. ...
... 5, 2012According to the Centers for Disease Control and ... has autism spectrum disorder (ASD), a broad group of ... fascinated by screen-based technology such as videogames and these ... described in an insightful Roundtable Discussion published ...
Cached Biology News:DNA sequences need quality time too - guidelines for quality control published 2Can videogaming benefit young people with autism spectrum disorder? 2
IC50: 3 ng/ml · Limit of detection: 0.9 ng/ml...
Request Info...
Request Info...
... Ambion's custom siRNA service provides the premium ... silencing research. Custom siRNAs can be readily ... base target sequence, or by providing the ... out Ambion's Silencer Validated and Silencer Pre-designed ...
Biology Products: